Baumeier Christian, Harms Dominik, Aleshcheva Ganna, Gross Ulrich, Escher Felicitas, Schultheiss Heinz-Peter
Institute of Cardiac Diagnostics and Therapy, IKDT GmbH, 12203 Berlin, Germany.
Department of Infectious Diseases, Robert Koch Institute, 13353 Berlin, Germany.
J Clin Med. 2023 Jul 31;12(15):5050. doi: 10.3390/jcm12155050.
The diagnosis and specific and causal treatment of myocarditis and inflammatory cardiomyopathy remain a major clinical challenge. Despite the rapid development of new imaging techniques, endomyocardial biopsies remain the gold standard for accurate diagnosis of inflammatory myocardial disease. With the introduction and continued development of immunohistochemical inflammation diagnostics in combination with viral nucleic acid testing, myocarditis diagnostics have improved significantly since their introduction. Together with new technologies such as miRNA and gene expression profiling, quantification of specific immune cell markers, and determination of viral activity, diagnostic accuracy and patient prognosis will continue to improve in the future. In this review, we summarize the current knowledge on the pathogenesis and diagnosis of myocarditis and inflammatory cardiomyopathies and highlight future perspectives for more in-depth and specialized biopsy diagnostics and precision, personalized medicine approaches.
心肌炎和炎症性心肌病的诊断以及特异性和病因性治疗仍然是一项重大的临床挑战。尽管新的成像技术迅速发展,但心内膜心肌活检仍是准确诊断炎症性心肌疾病的金标准。随着免疫组化炎症诊断技术的引入和持续发展,并结合病毒核酸检测,自引入以来,心肌炎的诊断有了显著改善。连同诸如微小RNA和基因表达谱分析、特定免疫细胞标志物定量以及病毒活性测定等新技术一起,未来诊断准确性和患者预后将持续提高。在本综述中,我们总结了目前关于心肌炎和炎症性心肌病发病机制及诊断的知识,并强调了未来在更深入、更专业的活检诊断以及精准、个性化医学方法方面的前景。